环氧合酶及其抑制剂与肿瘤防治的研究进展

中国临床药理学与治疗学 ›› 2006, Vol. 11 ›› Issue (1): 22-26.

环氧合酶及其抑制剂与肿瘤防治的研究进展

卢丽娜, 杨婷¹, 庄则豪²

福建省老年医院药剂科, 福州 350001, 福建 ;¹福建省血液病研究所, 福州 350001, 福建 ; ²福建医科大学消化系病研究室, 福州 350005, 福建

收稿日期:2005-10-08 修回日期:2005-11-25 出版日期:2006-01-06 发布日期:2020-10-23
通讯作者: 庄则豪, 通讯作者, 男, 博士, 副主任医师, 主要从事胃食管肿瘤临床与发病机制研究。 Tel:0591-87982521 E-mail:zhuang203@gmail .com E-mail:zhuang203@gmail .com
作者简介:卢丽娜, 女, 药师, 主要从事肿瘤药物应用研究。 Tel:0591-83105070-186 E-mail:lln999cn@yahoo.com .cn 庄则豪, 通讯作者, 男, 博士, 副主任医师, 主要从事胃食管肿瘤临床与发病机制研究。 Tel:0591-87982521 E-mail:zhuang203@gmail .com
基金资助:
福建省教育厅项目( №K02068)

Role of cyclooxyenase and its inhibitors in prevention and treatment of can- cer

LU Li-na, YANG Ting¹, ZHUANG Ze-hao²

Department of Pharmacy , Fujian Geriatrics Hospital, Fuzhou 350001 , Fujian, China ;¹Institute of Hematology of Fu- jian, Fuzhou 350001 , Fujian, China ;²Laboratory of Gastroenterology, Fujian Medical University , Fuzhou 350005, Fujian, China

Received:2005-10-08 Revised:2005-11-25 Online:2006-01-06 Published:2020-10-23

摘要/Abstract

摘要： 环氧合酶( COX) 及其抑制剂是近年肿瘤防治研究的热点之一。目前认为, COX 通过多种途径参与肿瘤的发生发展, COX 抑制对结肠癌等多种肿瘤有预防作用, 也可能增强肿瘤的放化疗疗效, 但安全性及有效性均不理想, 且可能存在非 COX 途径。因此, COX 作为肿瘤防治靶点的临床价值还有待进一步评价。

关键词: 非甾体类抗炎药, 选择性环氧合酶 2 抑制剂, 肿瘤治疗, 肿瘤预防

Abstract: Cyclooxygenase ( COX) and its inhibitors were widely studied for the prevention and treatment of cancer.It is believed that COX is involved in the carcino- genesis through different pathways .COX inhibitors play some roles in the prevention for colon cancer and many other cancers, and can enhance the effects of radio- and chemotherapy .However, the safety and efficacy of those agents are far form perfect .There has COX independent pathway counted for the anti-cancer effects of COX inhibi- tors as well.Therefore, further studies should be taken to evaluate the value of COX as a target of cancer prevention and treatment in clinical .

Key words: nonsteroidal anti-inflammatory drugs , selective COX-2 inhibitor ;oncotherapy ;cancer preven- tion

中图分类号:

R979 .1

卢丽娜, 杨婷, 庄则豪. 环氧合酶及其抑制剂与肿瘤防治的研究进展[J]. 中国临床药理学与治疗学, 2006, 11(1): 22-26.

LU Li-na, YANG Ting , ZHUANG Ze-hao. Role of cyclooxyenase and its inhibitors in prevention and treatment of can- cer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(1): 22-26.

参考文献

1 Kune GA, Kune S, Watson LF.Colorectal cancer risk, chronic illnesses, operations, and medications:case control results from the melbourne colorectal cancer study[ J] .Cancer Res, 1988; 48: 4399-404
2 Blanke C.Role of COX-2 inhibitors in cancer therapy[ J] .Can- cer Invest, 2004 ; 22: 271-82
3 Ratnasinghe D, Tangrea J, Roth MJ, Dawsey S, Hu N, Anver · 24 · Chin J Clin Pharmacol Ther 2006 Jan; 11( 1)M, et al .Expression of cy clooxygenase-2 in human squamous cell carcinoma of the esophagus;an immunohistochemical survey [ J] . Anticancer Res, 1999; 19: 171 -4
4 Lim HY, Joo HJ, Choi JH, Yi JW, Yang MS, Cho DY, et al . Increased expression of cyclooxygenase-2 protein in human gas- tric carcinoma[ J] . Clin Cancer Res, 2000 ; 6: 519-25
5 Oshima H, Oshima M, Inaba K, Taketo MM. Hyperplastic gastric tumors induced by activated macrophages in COX-2 mPGES-1 transgenic mice[ J] . Embo J, 2004; 23: 1669 -78
6 Rigas B, Kashfi K.Cancer prevention: A new era beyond COX-2 [ J] . J Pharmacol Exp Ther, 2005; 314 : 1-8
7 Tiano HF, Loftin CD, Akunda J, Lee CA, Spalding J, Sessoms A, et al .Deficiency of either cyclooxygenase ( COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumori- genesis[ J] . Cancer Res, 2002; 62 : 3395-401
8 Kelley DJ, Mestre JR, Subbaramaiah K, Sacks PG, Schantz SP, Tanabe T, et al .Benzo[ a] pyrene up-regulates cy clooxygenase-
2 gene expression in oral epithelial cells[ J] .Carcinogenesis, 1997; 18 : 795-9
9 Mesri M, Morales-Ruiz M, Ackermann EJ, Bennett CF, Pober JS, Sessa WC, et al .Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting [ J] . Am J Pathol, 2001 ; 158: 1757-65
10 Tsujii M, Kawano S, DuBois RN. Cy clooxygenase-2 expression in human colon cancer cells increases metastatic potential[ J] . Proc Natl Acad Sci USA, 1997 ; 94: 3336-40
11 Stolina M, Sharma S, Lin Y, DohadwalaM,Gardner B, Luo J, et al .Specific inhibition of cyclooxygenase 2 restores antitumor re- activity by altering the balance of IL-10 and IL-12 synthesis[ J] . J Immunol, 2000 ; 164: 361-70
12 Kishi K, Petersen S, Petersen C, Hunter N, Mason K, Masferrer JL, et al .Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor[ J] .Cancer Res, 2000 ; 60: 1326-31
13 Dicker AP, Williams TL, Grant DS. Targeting angiogenic pro- cesses by combination rofecoxib and ionizing radiation[ J] .Am J Clin Oncol, 2001 ; 24: 438-42
14 Hsueh CT, Chiu CF, Kelsen DP, Schwartz GK. Selective inhi- bition of cy clooxygenase-2 enhances mitomycin-C-induced apop- tosis[ J] .Cancer Chemother Pharmacol, 2000; 45 : 389-96
15 Hida T, Kozaki K, Muramatsu H, Masuda A, Shimizu S, Mit- sudomi T, et al .Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non- small cell lung cancer cell lines[ J] .Clin Cancer Res, 2000; 6 : 2006-11
16 Zhou XM, Wong BC, Fan XM, Zhang HB, Lin MC, Kung HF, et al .Non-steroidal ant i - inflammatory drugs induce apoptosis in gastric cancer cells through up-regulation of bax and bak[ J] . Carcinogenesis, 2001; 22: 1393 -7
17 Fan XM,Wong BC, Lin MC, Cho CH, Wang WP, Kung HF, et al . Interleukin-1 beta induces cyclo-oxygenase-2 expression in gastric cancer cells by the p38 and p44 42 mitogen-activated protein kinase signaling pathways[ J] .J Gastroenterol Hepatol, 2001; 16 : 1098-104
18 Jiang XH, Tu SP, Cui JT, Lin MC, Xia HH, Wong WM, et al . Antisense targeting protein kinase C alpha and beta1 inhibits gastric carcinogenesis[ J] . Cancer Res, 2004; 64: 5787 -94
19 Wong BC, Jiang X, Fan XM, Lin MC, Jiang SH, Lam SK, et al .Suppression of RelA p65 nuclear translocation independent of IkappaB-alpha degradation by cyclooxygenase-2 inhibitor in gastric cancer[ J] .Oncogene, 2003; 22 : 1189 -97
20 Wong BC-y, Jiang XH, Lin MCM, Tu SP, Cui JT, Jiang SH, et al . Cyclooxygenase-2 inhibitor ( SC-236) suppresses activator protein-1 through c-Jun NH2-terminal kinase[ J] . Gastroenterolo- gy, 2004; 126 : 136 -47
21 Williams JL, Nath N, Chen J, Hundley TR, Gao J, Kopelov- ich L, et al .Growth inhibition of human colon cancer cells by nitric oxide ( NO)-donating aspirin is associated with cyclooxy- genase-2 induction and beta-catenin T-cell factor signaling, nu- clear facto r - kappaB, and NO synthase 2 inhibition : implications for chemoprevention[ J] . Cancer Res, 2003; 63: 7613 -8
22 Waskewich C, Blumenthal RD, Li H, Stein R, Goldenberg DM, Burton J.Celecoxib exhibits the greatest potency amongst cy- clooxygenase ( COX) inhibitors for growth inhibition of COX-2- negative hematopoietic and epithelial cell lines[ J] . Cancer Res, 2002 ; 62: 2029-33
23 Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G. COX-2 independent induction of cell cycle arrest and apopto- sis in colon cancer cells by the selective COX-2 inhibitor cele- coxib[ J] . Faseb J, 2001; 15: 2742 -4
24 Eibl G, Takata Y, Boros LG, Liu J, Okada Y, Reber HA, et al . Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor[ J] .Cancer Res, 2005 ; 65: 982-90
25 Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al . The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis[ J] . N Engl J Med, 2000 ; 342: 1946-52
26 Higuchi T, Iwama T, Yoshinaga K, Toyooka M, Taketo MM, Sugihara K. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibi- tor, on rectal polyps in familial adenomatous polyposis patients [ J] .Clin Cancer Res, 2003; 9 : 4756-60
27 Phillips RK, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, et al .A randomised, double blind, placebo con- trolled study of celecoxib, a selective cyclooxygenase 2 inhibi- tor, on duodenal polyposis in familial adenomatous polyposis [ J] . Gut, 2002 ; 50: 857-60
28 Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, et al .Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis[ J] .N Engl J Med, 1993; 328: 1313 -6
29 Shureiqi I, Lippman SM.Lipoxygenase modulation to reverse carcinogenesis[ J] . Cancer Res, 2001 ; 61: 6307-12
30 Mao JT, Tsu IH, Dubinett SM, Adams B, Sarafian T, Baratelli F, et al .Modulation of pulmonary leukotriene B4 production by cyclooxygenase-2 inhibitors and lipopolysaccharide [ J] .Clin Cancer Res, 2004 ; 10: 6872-8
31 Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al . Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial[ J] .N Engl J 中国临床药理学与治疗学 2006 Jan; 11( 1) · 25 ·Med, 2005 ; 352 : 1092-102
32 Solomon SD, McMurray JJV, Pfeffer MA, Wittes J, Fowler R, Finn P, et al . Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention[ J] .N Engl J Med, 2005 ; 352 : 1071-80
33 Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al .Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheu- matoid arthritis:the CLASS study : A randomized controlled tri- al . celecoxib long-term arthritis safety study [ J] . Jama, 2000 ; 284: 1247-55
34 Fitzgerald GA.Coxibs and cardiovascular disease[ J] . N Engl J Med, 2004; 351: 1709 -11
35 Lin HJ, Lakkides KM, Keku TO, Reddy ST, Louie AD, Kau IH, et al . Prostaglandin H synthase 2 variant ( Val511Ala) in African Americans may reduce the risk for colorectal neoplasia [ J] .Cancer Epidemiol Biomarkers Prev, 2002; 11 : 1305-15
36 Fritsche E, Baek SJ, King LM, Zeldin DC, Eling TE, Bell DA. Functional characterization of cyclooxygenase-2 polymorphisms [ J] . J Pharmacol Exp Ther, 2001; 299: 468 -76

[1]	赵文超, 邱艳芳, 谭嵘. 肿瘤治疗中靶向DNA损伤反应[J]. 中国临床药理学与治疗学, 2020, 25(8): 943-952.
[2]	张锴婷，陈乃涵. 生物药在肿瘤治疗领域的临床研究进展[J]. 中国临床药理学与治疗学, 2020, 25(1): 32-43.
[3]	赵小彬，余陈欢，夏爱晓，俞文英，俞冰. 纳米载体特异性靶向TAMs治疗肿瘤的研究进展[J]. 中国临床药理学与治疗学, 2018, 23(7): 830-835.
[4]	许丽华，徐肖阳，徐骏军，俞文英. 表面修饰白蛋白纳米粒在肿瘤靶向治疗中的研究进展[J]. 中国临床药理学与治疗学, 2017, 22(8): 948-954.
[5]	张雪, 吴兰香, 张陶蓝, 温纯洁, 付利娟, 周宏灏. β-异硫氰酸苯乙酯多靶向抗肿瘤作用机制研究进展[J]. 中国临床药理学与治疗学, 2015, 20(2): 217-222.
[6]	马爱妞, 王永祥, 周向军. 靶向诱导DNA 甲基化与肿瘤治疗研究进展[J]. 中国临床药理学与治疗学, 2009, 14(3): 241-244.
[7]	朱毓, 吴美华. 非甾体类抗炎药与心血管疾病的研究进展[J]. 中国临床药理学与治疗学, 2008, 13(3): 350-354.
[8]	李哲, 袁守军. 表皮生长因子受体酪氨酸激酶抑制剂在肿瘤治疗中的应用[J]. 中国临床药理学与治疗学, 2004, 9(4): 361-364.